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LEUKEML\ AND RISK STRAPTJCAfiON ACCORDING TO 
SOKAL SCORE 
Naveen Naz Syed, Mohammad Usman, Gulnaz Khaliq: Salman N. Adil and Mohammad Khurshid 
ABSTRACT 
Objective: To compile the clinical and haematological parameters of chronic myeloid leukemia (CML) and risk stratification 
according to Sakal score in our population. 
Design: A descriptive analysis. 
Place and Duration of Study: The Aga Khan University Hospital, during the period from August 1997 to August 2005. 
Subjects and Methods: All patients with diagnosis of chronic myeloid leukemia treated as outpatient in haematology 
clinic, or admitted in haem-oncology wards in The Aga Khan University Hospital were included. Records were 
retrospectively analyzed for clinicopathologic features. Risk groups were assigned as per Sakal scoring. 
Results: During the 8 years study period, 245 patients with chronic myeloid leukemia were analyzed, the median age of 
presentation was 35 years (range 11-73); with male to female ratio 1.69:1. At the time of diagnosis, 178 patients (72.6%), 
48 (19.7%) and 17 (7.8%) of patients were in chronic, accelerated and blast phase of the disease respectively. Abdominal 
fullness was the frequent clinical presentation followed by fever. Laboratory parameters revealed mean hemoglobin 10.0 
g/dl (range 4.6-15), mean total leukocyte count 168x109fl (35·959) and mean platelets 408x109/L (range 30·2335). The 
mean size of spleen at the time of presentation was 9.2 em below the left subcostal margin. A large number of patients 
(46.2%) were in high risk group according to Sokal score i.e. > 1.2. 
Conclusion: CML occured more commonly at younger age in this series. Most of these patients were in high risk group 
according to Sokal score. 
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INTRODUCTION 
Chronic myeloid leukemia (CML). a clonal disorder, results 
from the neoplastic transformation of primitive hemopoietic 
stem cellt;l, in which cells of myeloid lineage undergo massive 
clonal expansion) The hallmark of CML is the formation of a 
BCR-ABL fusion gene4, results from reciprocal translocation of 
chromosomal material between long arm of chromosome 22 
and 9, an event referred as t(9;22) (q34;q11 ), Philadelphia 
chromosome (ph).5,6 
CML is a rare disease7; however, incidence appears to be 
constant worldwide. It occurs in about 1.0-1.5 per 100,000 of 
the population per annum in all countries where statistics are 
adequate.7 .8 
Most of the cases identified in 5th and 6th decades of life7; 
with the median age at diagnosis of CML is 50-60 years. Less 
than 10% of cases occur under 20 years of age.2.8,9 Recently 
there has been a decrease in proportion of patient aged above 
60 years)O The disease occurs slightly more often in men than 
women but have similar clinical manifestation and course.9 
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There is no familial predisposition and no definite association 
with HLA genotype has been recognized.?, s No contributory 
infectious agent has been incriminated.8 
Despite the presence of a uniform molecular abnormality, 
CML demonstrates a paradoxical clinical heterogeneity.tu,n 
Clinically, CML is characterized by biphasic or triphasic 
course, usually diagnosed in chronic phase in over 80% of 
cases.V> Approximately two-third of patients go through an 
intermediate phase known as accelerated phase before 
progression to blast phase.ll 
The presenting features of chronic myeloid leukemia are 
variable.2 ranging from silent disease to nonspecific symptom.r,; 
and signs including fatigue, weight loss, night sweats, 
hyperleucocytosis and splenomegaly mostly. 
Various clinical and laboratory parameters have been 
identified to have prognostic significance; based on these 
several prognostic models have been developed to classify 
patients in to risk groups with different prognoses.J2,13 Among 
them most widely used is one proposed in 1984 by Sokal and 
colleagues14; which helps to determine the aggressiveness of 
the disease and median survival. 
The objective of this study was to compile the clinical and 
haematological parameters of CML and risk stratification 
according to Sokal score in our population. 
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This was a descriptive study conducted during the period 
from August 1997 to August 2005. The files of all patients with 
a diagnosis of chronic myeloid leukemia treated as out-patient 
in hematology clinic, or admitted in haem-oncology wards in 
The Aga Khan University Hospital during the study period 
Were retrieved from medical record section, which use 
international classification of disease (ICD 9.0 version) 
database. 
The diagnosis of these patients was made by complete blood 
count done on Coulter S+IV (Coulter Electronics, Florida, 
USA); bone marrow aspirate and trephine and bone marrow 
cytogenetics. Where necessary; BCR/ ABL by polymerase 
chain reaction (PCR) was performed. The disease was 
classified into the chronic, accelerated or blast phases by using 
WHO criteria.lS These cases were analyzed for their clinical 
manifestations and hemograins. 
Sokal score was applied for risk stratification at the time of 
presentation by using four clinical variables: age; size of 
spleen; percentage of blast cells and platelet count. The hazard 
ratio (Sakal score) was calculated by entering data in the 
following equation.2,14 
Exp [0.116 (age- 43.4)] +0.0345 (spleen size-7.51) +0.188 
[(platelets/700)'-0.563] +0.0887 (blast %-2.10). 
This classification divides patients into three groups: low risk 
group (Sokal score <0.8), intermediate risk (Sokal 0.8-1.2) and 
high risk group in which Sakal score was > 1.2)4 
Data was presented as mean and median values. All data was 
analyzed by using SPSS program (statistical package for social 
SCiences) version 13.0. 
A total of 245 patients were diagnosed to have chronic 
myeloid leukemia, over a period of 8 years. The median age at 
the time of diagnosis was 35 years (range 11-73). Majority of 
patients, 154 (64%), were less than 40 years of age at the time 
of diagnosis. The peak incidence of CML (27%) was seen in 31-
40 years age group (Figure 1). 
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The series included 154 males (63%) and 91 females (37%). 
Male to female ratio was 1.69:1. At the time of diagnosis, 
chronic phase was seen in 178 patients (72.6%), 48 (19.7%) had 
accelerated phase of the disease and 19 (7.8%) were in blast 
transformation of chronic myeloid leukemia, according to 
WHOIS criteria for phase of the disease. 
The laboratory and clinical parameters that were observed at 
first time of presentation are shown in Table I. 
Table 1: Laboratory and clinical parameters at the time of presentation. 
Presenting features 
Routine blood tests 
Abdominal fullness 
Fever 
Fatigue 
Weight loss 
Bleeding episodes 
Cytopenias 
Hem~ra~---····-----­
Mean hemoglobin (g/dl) 
range 
101 (41.2%) 
97 (39.5%) 
69 (28.1%) 
40 (16.3%) 
23 (9.3%) 
14(5.7%) 
9 (3.6%) 
--------------
10.0 
4_6-15 2 
Mean total leukocyte count (x1 Q9/l) range 168 
35-959 
Mean platelet counts (x1 09/l) 
range 
Mean size of spleen (em) 
408 
30-2335 
9.2 em 
In most of the cases medical opinion was sought because the 
blood tests performed on a routine check-up, showed high 
white cell count. However, common presenting symptoms 
were abdominal fullness or distension, fever, fatigue and 
weight loss. 
At the time of presentation, 220 patients (89%) had enlarged 
spleen; complete blood counts revealed hyperleucocytosis 
(WBC >100x1Q9/I) in 121 (49%), anemia (hemoglobin <lOg/dl) 
in 93 (37.9%) and marked thrombocytosis (platelet >600xJ09(!) 
in 30 (12.2%) cases. 
At the time of presentation, patients were also classified into 
prognostic groups, using the Sokal formula. 44.9% of patients 
had Sakal score <0.8, which means they were in low risk 
group/ intermediate risk group comprised of 8.2% (Sokal score 
0.8-1.2) and 46.2% were high risk (Sokal score >1.2). 
Substantial number of pwtients who were in chronic phase of 
the disease fells into intermediate or high risk group. 
Cytogenetic studies were performed in all patients. In 234 
(95.5%) Philadelphia chromosome was detected, while 11 
(4.5%) had normal karyotype. Subsequently PCR studies were 
performed in these patients for BCR/ ABL translocation, 
which was found to be positive in all of them. 
OJ•;t L->SIU'\: 
Clinicopathologic aspects in chronic myeloid leukemia have 
not been studied in Pakistan. The aim of this study was to 
compile the local data in this regard. 
The incidence of CML is approximately 1 per 100,000 
population per year. In 2002, it is estimated that there will be 
4 400 new cases with 2,000 estimated deaths.16 Local data 
r~veals an incidence of CML in Karachi (1995-2002) is 
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1.2/100,000 in males and 0.8/100,000 in females' 7; the results 
are consistent with international studies.7)l 
The median age at the time of presentation has been reported 
53 years in Western literature2, but all age groups, including 
children, are affected.?)! In this series, peak incidence of 
disease was seen in younger population. These results are 
comparable with reports from India where chronic myeloid 
leukemia was seen in third and fourth decades18J9; similar 
results were found in few local studies as well.20,2l A study 
regarding breast cancer epidemiology from our country had 
shown that breast carcinoma occurs at a younger age group in 
(Karachi - Pakistan) than in western countries.22 It remains 
unclear as to why there are such geographical differences in 
age frequency in chronic myeloid leukemia as well. 
A regional study showed a higher male to female ratio; but in 
our series male to female ratio was 1.69, which is consistent 
with studies from other parts of world.2)l,23 
At time of presentation most of the cases (80-90%)2, .. 5,!9 are 
diagnosed in the chronic phase, however, in this series, 72.6% 
of pJtients were found in chronic phase of the disea:.:;e at the 
time of diagnosis; contrary to the reported incidence 
worldwide. This could be explained by the delay in medical 
presentation or referral bias since this was a hospital-ba:;ed 
study. 
The clinical findings at presentation of chronic myeloid 
leukemia vary in our series; this compares quite favorably 
with the result in the literature.23-2S The typical symptoms at 
presentation are abdominal fullness, fatigue, anorexia, and 
weight loss, but in about 20 to 50 percent of patients are 
asymptomatic, with the disease first being suspected from 
routine blood tests.24,25 With progressive bone marrow 
involvement, these patients may develop cytopeni<1s, various 
infections can occur as well as hemorrhage, anemia-related 
symptoms, and easy bruising with petechiae and purpura. In 
our group abdominal fullness was the commonest presenting 
complaint followed by fever, fatigue and weight loss. Small 
number of patients presented with bleeding from orifices or 
cytopenias during aggressive phase of the disease. 
The most common abnormality on physical examination is 
splenomegaly, which is present in upto half of patients)] 
Hepatomegaly and lymphadenopathy may be prl'st'nt, and 
result in a sensation of abdominal fullness <1long with 
discomfort and early satiety .. 2s Although lymphadenopathy is 
uncommon in chronic-phase CML, it may develop with more 
advanced stages of the disease.7)l Some patients with chronic 
leukemia may present with hyperleukocytosis that can result 
in marked splenomegaly. Marked thrombocytosis may present 
in some cases, which is consistent with the presence of a defect 
in a pluripotent hematopoietic stem celJ.7 )l 
Faderl et af.24 and Savage et a/.25, reported splenomegaly (48 
and 76 percent), anemia (45 and 62 percent), white blood cell 
count above 100,000/cmm (52 and 72 percent), and platelet 
count above 600,000 to 700,000/cmm (15 and 34 percent) at 
time of diagnosis. Although, presence of enlarged spleen at the 
time of diagnosis was more prevalent in our population, but 
the frequency of hyperleucocytosis, anemia or thrombocytosis 
are almost comparable with the internationalstudiesJ-8,24-25 
Presence of enlarged spleen is unexplainable in our 
population; it might be because of delay in presentation or 
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might be due to high white blood cell count; however, it was 
associated with bad prosrno~is in one series_21 
Patients with chronic-phase CML usually have a longer 
survival than those with the more advanced phases of the 
disease.? However, prognostic systems have been proposed to 
help better predict outcomes. Sokal et a/.14 found age, spleen 
size, platelet count, and the percentage of blasts to be 
independent prognostic factors. 
Large number of patienLc; in this series were in high risk group 
(Sokal score > 1.2). This might be because of late presentation; 
prev~lence of enlarged spleen in large number of patients, 
delay in the diagnosis and substantial number of patients were 
in aggressive or blast phase of the disease at the time of 
diagnosis .. Sinclair el af.4 reported poor prognosis in patients 
with high sokal score in chronic phase.4 
There was characteristic balanced reciprocal translocation of 
chronic myeloid leukemia between the long arms of 
chromosomes 9 and 22 t(9;22) in 95.5% of cases which is 
similar to the reported incidence that is 90% to 95% of 
patients.J-2,7 
There were several limitations of the study. The data was 
collected retrospectively, <1nd was only of patients who 
presented to our center either for management or diagnostic 
workup, so the total number of patients diagnosed, age groups 
and prognostic scores might not be the exact representative of 
our population. 
Chronic myeloid leukemia affects people at young age in this 
region, mostly in third decade with male predominance. 
Abdomina! fullness/distension or fever was the conunonest 
presenting complaints. Majority of patients were in chronic 
phase with high white cell counts and enlarged spleen. 
Substantial number of patients was in aggressive phase of 
disease according to Sokal score. 
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